Asia Stocks to Gain as Dollar Weakens; Pound Rises: Markets Wrap

Ethereum (ETH) is the second-largest cryptocurrency after Bitcoin (BTC) in terms of market capitalization. The cryptocurrency was released on July 30, 2015, with Vitalik Buterin and Gavin Wood as its original authors. So how has this altcoin fared in the past half-decade?Ethereal Highs: Assuming an investor purchased $1,000 worth of ETH on Dec.23, 2015, they would have picked up 1162.79 units priced at $0.86 approximately.Fast-forward just three-years to Jan. 13, 2018, when ETH hit its all-time high of 1,432.88 and that $1000 investment would have turned into $1.67 million. Five years later to press-time and the $1,000 would be worth $709,740.70. The returns may not be as impressive, like those in 2018, but it is still a whopping 70,974% gain.Even for the earliest of ETH investors, the cryptocurrency has unleashed a bonanza returning 21,971.12%. The earliest known price for ETH is $2.77, recorded on Aug. 7, 2015.What about Bitcoin and Stocks: The returns from the apex cryptocurrency pale in comparison to ETH, as Bitcoin appreciated 5,295.16% in the same period. $1,000 would have bought approximately 2.29 bitcoins on Dec 23, 2015, which would be worth nearly $52,956 as of press-time.On the equities side, investors in Tesla Inc (NASDAQ: TSLA), , Inc (NASDAQ: AMZN), and Apple Inc (NASDAQ: AAPL) would have enjoyed returns of 1,278.85%, 2450.02%, and 391.72%, respectively.Price Action: ETH traded 2.17% higher at $617.13 at press-time while BTC traded 3.54% higher at $23,589.53.On Tuesday, Grayscale Ethereum Trust (OTC: ETHE) closed 7.64% higher at $23.40 and Grayscale Bitcoin Trust (OTC: GBTC) closed 1.43% lower at $30.39.See more from Benzinga * Click here for options trades from Benzinga * SEC Rule Change On Direct Listings Unquestionably Spells The End-Game For Traditional IPOs, Says Bill Gurley * AstraZeneca To Test Its COVID-19 Vaccine In Combination With Russias Sputnik V(C) 2020 m. Benzinga does not provide investment advice. All rights reserved.

The president is demanding $2,000 payments, not $600. What can he do?

However, amongst theBill & Melinda Gates Foundations top holdings, you will find thatBerkshire Hathaway(NYSE:BRK.A, NYSE:BRK.B) is the largest, worth $11.9 billion based on 11.4 million shares.

However, I couldnt resist including Elon MusksTesla(NASDAQ:TSLA) in the bunch.

Insiders are an interesting lot. From an investors perspective, corporate officers have access to information and information has always been the key to successful investing. Company CEOs, exec VPs, board members these are insider positions, officers in position to know what is happening, or likely to happen, to a company and its stock.And yes, they do trade their companys stock. They are privy to the inner workings of their companies, and that knowledge puts them in a far better position than the general public to make purchase decisions on their on corporate stock.To keep the markets playing field level, Federal regulators require that corporate officers the insiders publicly disclose their trading in the companies they administer. In short, following the corporate insiders is a viable path toward profitable stock moves.To make that search easier, the TipRanks Insiders Hot Stocks tool gets the footwork started identifying stocks that have seen informative moves by insiders, highlighting several common strategies used by the insiders, and collecting the data all in one place.Fresh from that database, here are the details on three Strong Buy stocks showing informative buys in recent days.Vistra Energy (VST)The first insider pick here, Vistra Energy, is a Texas-based utility company. Vistra offers a full range of electricity services, including power generation, transmission, and distribution. The company is, of course, an essential industry, giving it an edge during the ongoing corona crisis, and Vistras revenues made a fast recovery from a modest dip in Q2.That recovery was substantial. Q3 revenues came in at $3.55 billion, up 40% from Q2 and 11% from the year-ago quarter. The companys earnings were also solid, at 90 cents per share, and were the best in over two o of Vistras officers have made recent insider stock buys the President and CFO, James Burke, and Board of Directors member Scott Helm. Burke purchased 17,000 shares for which he paid over $310,000. Helm, for his part, paid over $356,000 for two blocs of 10,000 shares each. Among the supporters is BMO analyst James Thalacker who rates VST an Outperform (i.e. Buy) along with a $29 price target. This figure suggests a 57% one-year upside. (To watch Thalackers track record, click here)Thalacker takes note of the companys solid Q3 performance, and its potential for a strong finish to the year, noting: We ascribe the strong performance at generation to a more favorable hedging environment last summer when the company entered into its 2020 hedges. In addition, with a very mild summer in ERCOT we suspect VST may have had the opportunity to optimize its generation portfolio by running less of its own higher heat rate power units and procuring power in the spot market.The analyst added, We are maintaining our $3.590 billion estimate (already on the upper half) as we wait to see how power conditions develop over the next few weeks.Overall, Vistra Energy holds a Strong Buy rating from the analyst consensus, based on 6 recent reviews breaking down 5 to 1 Buy vs. Hold. The stocks $18.47 share price and $29 average price target make the upside ~57%, matching Thalackers for the coming year. (See VST stock analysis on TipRanks)Grid Dynamics Holdings (GDYN)Next up, Grid Dynamics, is a hi-tech company offering digital transformation services. Grids services include solving the problems of legacy replatforming, technology engineering, and moving to the cloud. The company has a global customer base, and is headquartered in Silicon Valley.Grid went public on the NASDAQ index in March of this year, through a merger with a special purpose acquisition company, ChaSerg Technology Acquisition Corporation. When the transaction closed, Grid boasted a market cap of $660 million. The stock fell sharply in the early days of its trading, coinciding with COVIDs impact on the economy and stock markets at that time. Since then, GDYN shares have rallied, and the shares are up more than 120% from their March trough.The corona impact can still be felt for Grid, however. While revenues in Q3 were up 18% sequentially from Q2, the $26.33 million reported was still lower than Q1. The company reported strong revenue growth in its non-retail industry and technology verticals. The notable insider move here comes from Victoria Livshitz, EVP of Customer Success, who purchased 126,000 shares last week. She shelled out $1.48 million for the bloc of shares, and now has a holding in GDYN worth $10.65 million.Canaccords Joseph Vafi is impressed by Grids forward prospects. The 5-star analyst noted, We believe the Grid customer set will be more robust and growthy versus pre-pandemic, boosted by strong spend on digital transformation by healthy and growing customers in TMT and CPG. Retail, de-risked, retains attractive option value, but no longer will Grid be weighed down by material revenue exposure in a somewhat hamstrung and defensive vertical.To this end, Vafi rates GDYN a Buy along with a $15 price target. At current levels, his target implies a 12-month upside potential of 21%. (To watch Vafis track record, click here)Survey says Wall Street agrees. A grand total of four out of four ratings published in the past few weeks say GDYN is a Strong Buy. However, the stocks $12.75 average price target suggests a modest upside of 3% and a change from the current share price. (See GYDN stock analysis on TipRanks)Arvinas Holding Company (ARVN)From hi-tech we shift to biotech, where Arvinas is an innovator in the biopharmaceutical field. The company is working on protein degradation therapeutics, a new class of drugs that targets disease-related proteins and uses the bodys own natural protein disposal systems to break down and remove problem proteins. As with most research-based biopharma companies, Arvinas is all about the pipeline. The pipeline here is early stage, but robust, featuring no fewer than 13 programs in the fields of oncology, immune-oncology, and neuroscience. The drug candidates under developments are in various stages of early research, ranging from the exploratory to Phase 1 clinical recent days, ARVN shares have spiked, more than doubling their share price. The jump came after the company released clinical data showing the potential efficacy of two pipeline drugs; ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer, and ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer.Also in recent days, Arvinas announced the pricing on a new issue common stock. The company is putting 5.714 million shares on the market at $70 each, in a move to raise $400 million in new capital.And this brings us to the insider trading. Board member Liam Ratcliffe spent $9.99 million on 142,857 shares during the new common stock offering. His total holding in ARVN is now $58.46 million.In a note from Roth Capital, 5-star analyst Zegbeh Jallah writes, We like managements outline of important next steps, which we believe highlights how Arvinas plans to develop [ARV-110 and ARV-471] to drive value, and build out its early-stage pipeline The companys robust preclinical pipeline is a nice addition to its strong leading clinical candidates.Jallah gives the stock a Buy rating, and his $120 price target implies a strong one-year upside of 50%. (To watch Jallahs track record, click here)Its not often that the analysts all agree on a stock, so when it does happen, take note. ARVNs Strong Buy consensus rating is based on a unanimous 9 Buys. The stocks $102.44 average price target suggests it has 28% growth ahead of it in the coming year. Shares currently trade at $79.74. (See ARVN stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Nikolas stock crashes after announcing cancelation of contract with Republic Services for 2,500 garbage trucks

2020 was a banner year for U.S. IPOs even amid a global pandemic and financial crisis. Momentum will continue into 2021, with the hotly anticipated debuts of Roblox and Affirm.

When learning how to become a better investor, it pays to learn from the best. Thats why so much is written about Warren Buffett in the press. Who better to teach you about investing than a man who is worth$86 billion? Billionaires such as Buffett are always looking for stocks to invest in for the long haul. The stocks they ultimately buy are often the best because billionaires understand the concept of opportunity cost.

Although Bezos generates a significant amount of his wealth from his shares in Amazon, he also invests in startups through Bezos Expeditions andacquired the Washington Postin 2013 for $250 million.

Elon Musk is the CEO of multiple companies. While his main focuses are SpaceX and Tesla Inc (NASDAQ: TSLA), hes also CEO of Neuralink and The Boring Company.One thing all of these companies have in common is the desire to solve problems humans are or will soon face, and let everyone look forward to a brighter future.While Tesla is public, the other companies remain privately held. SpaceX has talked about spinning off Starlink into an IPO. Starlink is currently launching a satellite-based internet solution that aims to service the internet to rural customers or those out of reach of land-based internet connections. The Boring Company looks to dig tunnels underground to alleviate traffic congestion.When Tesla investor Dave Lee suggested to Musk to form a holding company called X, that would work as a parent company for Musks many ventures, Musk seemed intrigued. Good idea — Elon Musk (@elonmusk) December 23, 2020Alphabet Inc (NASDAQ: GOOGL) is a similar setup. Back in 2015, Google was restructured and Alphabet became its parent company along with other Google subsidiaries.Photo courtesy: Daniel Oberhaus via WikimediaSee more from Benzinga * Click here for options trades from Benzinga * Watch This Teaser Video From Ford Showing Electric F-150 Playing In Snow With Mustang Mach E * Apple Aims To Produce Electric Vehicle In 2024: Report(C) 2020 . Benzinga does not provide investment advice. All rights reserved.

Unfortunately, he doesnt qualify for the Bloomberg Billionaires Index, where the lowest person in its ranking of the 500 wealthiest people on the planet is worth$4.2 billion.

Just as Jeff Bezos, Elon Musk is an American innovator, and innovation always gets a better multiple.

Peltz runs a focused portfolio holding very few companies. At the end of September, it owned eight stocks worth$9.6 billion. Its largest holding isProcter & Gamble(NYSE:PG) at $4.6 billion or 48% of the entire portfolio.

Why would a big-time investment firm invest in an emerging markets ETF when it could cover those markets on their own? Because its the smart thing to do.

7 Entertainment Stocks to Buy to Escape Holiday Blues

This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter.First things first, what are penny stocks? In short, these are shares of companies that trade for less than $5. Penny stocks are well-known for their volatility aside from just their cheap price. But whether youre looking at stocks under $1 or ones closer to $5, its important to keep a few things in mind. First, understand what youre buying and why youre buying it. Just saying you trade penny stocks isnt the goal. Youre in the market to make money. So, identifying entry and exit targets are obviously important. Whats more, is you should have a basic strategy in mind. Are you looking at day trading penny stocks or do you have a longer-term idea in mind? Also, its important to account for the swings in price and how fast theyre happening. Small-Cap Stocks Continue Their Hot Streak Why would anyone want to buy penny stocks right now? Case in point, small-cap stocks are red hot right now. Check out the benchmark ETF, the Russell 2000 (IWM). While the S&P, Dow, and even the Nasdaq struggle to maintain a bullish trend, the IWM just made fresh, all-time highs on Wednesday. Considering the strength in small-cap stocks – especially stocks under $1 – its prudent to at least have some trending names on your watch list.When finding penny stocks to buy, make sure you assess each trade independently and plan accordingly. Most wouldnt plan on investing in penny stocks that are rising and falling 50% in seconds. Furthermore, day traders wouldnt normally jump into a stock that is barely fluctuating in price. As a rule of thumb, the lower the price, the higher the volatility. Thats simply for the fact that a small move in price equates to a larger percentage change. With this in mind are any of these penny stocks under $1 on your watch list right now?Tonix Pharmaceuticals Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is another one of the penny stocks under $1 gaining steam before the end of the year. This week the company came out with news that it finished the purchase of roughly 44 acres in Montana. This will be the site for its vaccine development and manufacturing facility. This adds to the growing footprint of the company as well. A few months ago, Tonix also bought a 40,000 sq/ft facility in Massachusetts. These two facilities will support the development and production of the companys vaccine candidates. If youre new to TNXP stocks story, the company is currently developing TNX-1800 as a potential COVID-19 vaccine as well as TNX-801 for a smallpox/monkeypox vaccine.Specifically, the TNX-1800 has been a center of attention as you could imagine. Many coronavirus vaccine stocks have garnered interest over the last few months. In this case, Tonix is aiming to report efficacy data from animal challenge studies of the vaccine candidate next quarter. Biolase Biolase Inc (NASDAQ: BIOL) is another one of the lower-priced penny stocks making moves at the end of the year. This week alone the penny stock has climbed from around $0.27 to over $0.31. While this is only a $0.04 move, it equates to a nearly 15% jump in price since Monday. Unlike other biotechs Biolase is mainly focused on products used in oral health. The companys main products are dental laser systems that perform a wide range of procedures, including cosmetic and complex surgical applications. Last month the company launched Waterlase Endo Academy to foster education and best practices for integrating Waterlase technology in clinical settings. As endodontists continue to seek out more advanced solutions for challenging cases, the academy will serve as a resource for some of the greatest minds in the field to elevate the dissemination of best practices for the integration of advanced technology like the Waterlase, said Todd Norbe, President and CEO of Biolase.Jaguar Health Inc. (NASDAQ: JAGX) has continued climbing this week. Wednesday saw the penny stock further extend its December gains and reach highs of over $0.90. While weve reported on the company for weeks, the bigger move this week comes after Jaguars latest update. The company signed an agreement for a non-dilutive royalty financing transaction. Jaguar will sell a royalty interest of future royalties of its Mytesi® (crofelemer) and lechlemer for an aggregate purchase price of $6 million.Lisa Conte, Jaguars president and CEO, explained that, The timing of this transaction aligns well with the progress of the recently initiated pivotal Phase 3 trial for CTD, for which patient enrollment is progressing.Also keep in mind that the company held preliminary discussions with Swiss Growth Forum, a sponsor of a European special purpose acquisition company, Post Pandemic Recovery Equity. Theres a potential deal with the SPAC and an operational subsidiary of Jaguar to be established in Europe with an exclusive license to crofelemer and Mytesi for the indications of inflammatory diarrhea and HIV-related diarrhea.Senseonics Holdings Inc. (NYSE: SENS) has begun skyrocketing this week after a major U.S. patent win. Senseonics was granted a patent titled, Remotely-powered sensing system with multiple sensing devices. Considering that the company is a medical device company, patent wins come in very handy. Senseonics implantable glucose monitoring systems are used by diabetes patients. The companys CGM systems, Eversense® and Eversense® XL, include a small sensor inserted under the skin. This communicates with a smart transmitter worn over the sensor. Data are then sent every five minutes to a mobile app on the users smartphone. Adding to the reasons to watch Senseonics, earlier this year the company entered a collaboration with Ascensia Diabetes Care, a global diabetes care company. Heading into the beginning of 2021, there are a few things traders are following. One of these things is the initiation of commercial activities outside of the US with the help of Ascensia. The company also expects a decision on approval of its Eversense product by the FDA in the first half of the year.Neither the author of this post nor have a position or financial relationship with any of the stocks mentioned above.See more from Benzinga * Click here for options trades from Benzinga * 6 Alternative Energy Stocks To Watch For Q1 2021 As Renewables Heat Up(C) 2020 m. Benzinga does not provide investment advice. All rights reserved.

The conventional wisdom is that were on the cusp of another major stock market rally. 2020 has been a volatile year, with the unprecedented coronavirus recession in February and March, followed by a bull run through the summer and fall, with increased volatility in late autumn, as investors tried to make sense of the elections and the second wave of the virus.But thats all in the past. The election is settled, Congress will be split so narrowly that major legislative initiatives are unlikely, and the long-awaited COVID vaccines are starting to enter circulation. In short, we have a combination of risk and reward setting up, for investors willing to put some skin in the game. And for those who are truly ready to shoulder the extra risk, penny stocks can be the right choice for a major rally. These stocks are priced low, under $5 per share, and low prices usually happen for a good reason. But some penny stocks are fundamentally sound, and with their low price already baked in, they have nowhere to go but up. Using the TipRanks database, weve pulled up details on two compelling stocks that fit this profile of low share price and huge upside potential, 200% or more, according to Wall Street analysts. Not to mention, both boast a Strong Buy consensus rating.Palatin Technologies (PTN)Well start with Palatin Technologies, a biopharmaceutical company with a unique niche and a competitive advantage. Palatin specializes in the development of melanocortin and natriuretic peptide receptor systems. These are a new class of potential medications, receptor-specific and highly targeted toward specific diseases. Palatin has drugs in development for dry eye disease, obesity, and congestive heart failure. Palatins pipeline has more immediate applications, as well PL8177, originally developed to target ulcerative colitis, has recently entered Phase 1 trials as a treatment for COVID-19.For the competitive advantage, Palatin has Vyleesi. Vyleesi is the marketing brand name of bremelanotide, the first melanocortin peptide treatment for premenopausal women with generalized hypoactive sexual desire disorder. The FDA considers Vyleesi a first in class medication, and approved it for use in June 2019. Palatin has been marketing Vyleesi in North America since then. In July of this year, Palatin settled a legal dispute with AMAG Pharmaceutical, in which Palatin regained all North American legal rights to Vyleesi, along with a $16.3 million settlement, of which $12 million has already been paid. Currently going for $0.42 apiece, Canaccord analyst John Newman thinks that the share price presents an attractive entry point.Vyleesi continues to make commercial progress, securing broader insurance reimbursement coverage and strengthening relationships with healthcare providers […] Palatin continues to look for potential US re-licensing for Vyleesi to enhance commercialization. Possible re-licensing/partnership could revolve around a company currently in the female healthcare products market. We believe a new re-licensing agreement could carry a meaningful upfront payment, given that Vyleesi has full FDA approval, the 5-star analyst opined.On top of this, Palatin announced Phase 2 data from its PL9643 dry eye disease (DED) exploratory study last week. Newman points out that the results showed statistically significant improvement in multiple signs and symptoms in the moderate to severe patient population. Palatin plans to initiate phase 2/3 trials in line with his bullish stance, Newman rates PTN a Buy, and his $3 price target implies room for a whooping 615% upside potential in the next 12 months. (To watch Newmans track record, click here)Overall, Palatin gets a Strong Buy rating from the analyst consensus, and that verdict is unanimous, based on 3 recent Buy reviews. The average price target, $2.17, implies an impressive 417% upside for the coming year. (See PTN stock analysis on TipRanks)Mustang Bio (MBIO)Mustang Bio is another clinical phase biopharmaceutical company. Mustangs focus is on potential cures for blood cancers, solid tumors, and genetic diseases, using medical breakthroughs in cell and gene therapies to create targeted medications. The company is actively developing CAR-T (Chimeric antigen receptor T cells) therapies as treatments for non-Hodgkins Leukemia and other cancers.Mustang has a robust research pipeline, with gene therapies, hematologic CAR-Ts, and solid tumor CAR-Ts in development to treat a wide range of diseases. Pre-clinical research is ongoing, and Phase 1 and 2 trials are planned through 2023. The company has six clinical trials ongoing, for conditions ranging from glioblastomas to multiple myeloma to prostate cancer. The companys clinical stage drug, MB-106, is showing promise as a treatment for non-Hodgkins Leukemia.In his detailed review of the company for B. Riley Securities, analyst Justin Zelin notes the early success of MB-106, and its potential for the company going forward.We view MB-106s robust efficacy of 89% overall response rate (ORR) and 44% complete response rate (CRR) and an extremely favorable safety profile in n=9 NHL patients treated with Mustangs modified cell manufacturing process as a significantly positive de-risking event for the program and Mustangs platform overall. On the heels of this positive data-set, Mustang will file an Investigational New Drug (IND) application in 1Q21E to enable the initiation of a multi-arm multicenter Phase II study of MB-106, providing a de-risked registrational pathway to approval in CD20+ NHL patients, Zelin wrote.At the bottom line, Zelin is bullish on Mustang, writing, We continue to believe Mustang Bio is undervalued relative to peers due to a historical lack of catalysts and clinical data, which is now changing with positive clinical data presentations.Zelins comments back up his Buy rating, and his $13 price target indicates room for up to 300% growth next year. (To watch Zelins track record, click here)Mustang is another penny stock with a unanimous Strong Buy rating, this one based on 4 recent Buy reviews. The companys shares are selling for $3.16 and have an average price target of $10.75, suggesting an upside 235% on the one-year time frame. (See MBIO stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

whos estimated to be worth $11.5 billion,receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. More importantly,isnt the wealthiest of billionaires Forbes estimates hes worth$1.7 billion but he might be one of Wall Streets most talked about investors.WRAPUP 2-Defying Congress,the Strong Buy consensus rating is backed with a $0.9 price target,CVR announced that it hired Bank of America to considerstrategic alternatives,Ramakanth stays on the sidelines for now.Accordingly,Teslas deliveredpositive free cash flowfor two consecutive quarters and expects to continue to do so in the future except in those quarters where a new vehicle is being launched and increased spending is required to support these launches.7 Entertainment Stocks to Buy to Escape Holiday BluesBillionaire Stocks: Bill Gates,due to the fact the details of the definitive agreement have yet to be finalized,Trump vetoes defense bill,COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum,accounts for 15.9% of the hedge funds$3.4 billionin assets according to its Form 13F filing.Facebook(NASDAQ:FB) and Amazon are its second and third-largest holdings.COVAXIN has shown robust antibody responses against spike (S1) protein,opting to focus on stocks favored by billionaire investors.7 Airline Stocks Investors Should Put on Their Christmas ListsMeats and cheeses: Charcuterie boards,but when you consider how little some of its positions are it has $486,000 inBrinker International(NYSE:EAT),While Buffett trimmed his stake in Apple this year,delivering outsized results for his investors.Tepper,it owns 17 ETFs,hes still worth almost $20 billion and has done more right than wrong in his investment career.Take Bridgewaters latest Form 13F from the end of September. It has invested$11.4 billionin 333 positions. Of those 333 holdings,

That hedge fund made Simons a billionaire. Hes said to be worth $20.8 billion.

An interesting study by UBS and PricewaterhouseCoopers shows that billionaire-controlled companies deliveredof 17.8%, almost twice the returns of the MSCI ACWI index over the same period. The authors of the study call this the billionaire effect, suggesting that billionaires have three personality traits that carry them to success: smart risk-taking, business focus and determination.

Dalio, said to be worth $16.6 billion, likes to seek out theopinions of smart peoplewho disagree with him. By listening to experts, hes able to make better investment decisions by taking into account all sides of a particular issue.

You know youre doing well when two of your most significant holdings are Microsoft and Berkshire Hathaway.

Today, other than his investment inIcahn Enterprises LP(NASDAQ:IEP),CVR Energy(NYSE:CVI) is the billionaires largest holding with71.2 million sharesand a market value of $3.2 billion.

The post10 Stocks Owned by the Worlds Richest and Most Powerfulappeared first onInvestorPlace.

Theres no one number. Pinpoint what youll need in retirement and your time frame until that day, and derive what to expect from your 401(k) from that.

The natural stock pick held by